American BriVision unveils positive ABV-1504 phase II results
Category: #health  By Pankaj Singh  Date: 2019-06-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

American BriVision unveils positive ABV-1504 phase II results

Clinical stage biopharmaceutical company American BriVision has reportedly released positive outcomes of its ABV-1504 Phase II clinical trial, under Taiwan FDA clinical protocol code of BLI-1005-002 and the U.S. Food and Drug Administration, for major depressive disorder.

As per trusted sources, the trial was randomized, placebo-controlled, double-blind, and multi-centered, comprising 60 adult patients having moderate-to-severe MDD. Patients reportedly received a PDC-1421 high dose of 2 x 380 mg, PDC-1421 low dose of 380 mg or placebo for 6 weeks, three times a day.

For the record, the drug candidate PDC-1421 is the active therapeutic ingredient of ABV-1504. A high dose of PDC-1421 attained the primary prespecified endpoint by depicting an extremely significant 13.2-point drop in the Montgomery-Åsberg Depression Rating Scale total score through Intention-To-Treat analysis, assessed over the 6-week treatment period from baseline, compared to a 9.2-point drop in the placebo group. These outcomes further support the development of PDC-1421 in MDD, cited sources familiar with the trial.

According to Dr. Howard Doong, CEO of American BriVision, the company believes that the positive Phase II outcomes of its lead drug candidate PDC-1421 favors firm’s approach of utilizing botanical active pharmaceutical components to develop the drug.

Data by the World Health Organization suggests that over 300 million people of all ages are affected by MDD or clinical depression, worldwide. In the United States, more than 16 million adults, or around 7% of the population above the age of 18 suffer from MDD and it is the top cause of disability for ages between 15-44 in the country.

For the record, American BriVision’s aims to utilize its licensed technology to perform proof-of-concept trials via Phase II of the clinical development process at some of the world’s most eminent research institutions such as Stanford University, Cedars-Sinai Medical Center, and the University of California at San Francisco, then generate global sales by out-licensing the products to international pharmaceutical firms for Phase III studies, reported sources.

Source Credit https://www.globenewswire.com/news-release/2019/06/05/1864963/0/en/American-BriVision-Announces-Positive-Phase-II-Part-2-Results-for-ABV-1504-for-Major-Depressive

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
By Pankaj Singh

Genentech, Inc., a subsidiary of the Roche Group, has reportedly announced the completion of a sBLA (supplemental Biologics License Application) submission to the U.S. FDA (Food and Drug Administration) for Tecentriq ® (atezolizumab) in combinati...

FDA issues a cybersecurity warning for GE medical equipment
FDA issues a cybersecurity warning for GE medical equipment
By Pankaj Singh

The U.S. Food and Drug Administration, an agency within the U.S. Department of Health and Human Services, recently issued a safety communication informing patients, health care providers and facilities regarding the cybersecurity vulnerabilities...

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...